~~<i id='02B55583B0'><strike id='02B55583B0'><tt id='02B55583B0'><pre id='02B55583B0'></pre></tt></strike></i>~~

Home» focus» entertainment

entertainment

author：hotspot 2025-09-28 06:21:53 Page View：36319

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Future doctors need a strong humanities education
Next article： Dobbs anniversary: the lost opportunity of abortion as health care

explore

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

Head of FDA's diagnostics center, who led through Covid, retires

TimothyStenzelledtheFDA'sdiagnosticsdivisionduringtheCovid-19pandemic,astheagencyscrambledtopushthro

As demand for Covid shots wanes, Moderna seeks its next success

RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

Maisha Meds is a PBM, but don't call it that

ZachariahKirimiisapharmacistwhousestheMaishaMedsapptohelpmanagehisinventoryandoffersubsidizedproduct